Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Gene Therapy
Gene Therapy · The big question

First inside-the-body CRISPR gene therapy heads to the FDA

Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy

Nature Biotechnology2 min readAI-assisted summary
Editorial illustration for Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy
Editorial illustration

Summary

Intellia Therapeutics is making medical history as it seeks approval from the US Food and Drug Administration for a groundbreaking genetic treatment. The drug, called lonvoguran ziclumeran or lonvo-z, is the first CRISPR-based gene therapy designed to work "in vivo," meaning the genetic editing happens directly inside the human body. CRISPR is a biological tool that allows scientists to make precise changes to DNA. Intellia is using this technology to treat hereditary angioedema, a genetic condition that causes severe and unpredictable swelling attacks.

The company recently completed a Phase 3 clinical trial, which is the final testing step before seeking regulatory approval. In the study, a single dose of lonvo-z reduced swelling attacks by 87 percent compared to a placebo over a six-month period. Even more strikingly, 62 percent of the patients who received the treatment had absolutely no attacks during those six months and were able to completely stop taking their usual preventative medications.

While these numbers are highly encouraging, the research does come with a few early caveats. The trial was relatively small, involving a total of 80 patients, with 52 receiving the actual therapy and 28 given a placebo. Additionally, the currently reported results only track the patients for six months. Researchers will need to monitor these individuals for a longer period to confirm that the single dose continues to work safely and effectively over time.

Why it matters.

This milestone represents a massive leap forward for the entire field of genetic medicine. Until now, the CRISPR therapies that have reached advanced stages or market approval generally require extracting cells from a patient, editing those cells in a laboratory, and then infusing them back into the body. By proving that an inside-the-body CRISPR treatment can successfully meet its clinical goals, Intellia is paving the way for a much simpler, more accessible patient experience. A successful one-time treatment could dramatically improve the quality of life for people with hereditary angioedema by freeing them from a lifetime of continuous preventative medications.

Beyond this specific disease, regulatory approval of lonvo-z would open the door for treating a wider variety of genetic disorders directly within the body. If the FDA ultimately clears this drug, it will signal to the biotech industry that in vivo gene editing is a viable commercial reality. This could accelerate future investments and research into single-dose treatments for other serious genetic diseases.

From the source

The story in numbers.

Reduction in attacks vs placebo for six months
87%
Patients attack-free and off preventative therapy
62%
Total patients enrolled in Phase 3 trial
80
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Gene Therapy

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

For decades, doctors have used harmless viruses known as adeno-associated viruses, or AAVs, as biological delivery trucks to treat genetic diseases. These viruses are engineered to carry healthy genes directly into a patient's cells. But a newly published study reveals an unexpected complication. Researchers recently linked a specific brain tumor in a five-year-old boy to an AAV9 gene therapy he received as an infant to treat an inherited disorder called MPS1 deficiency. When the boy was five, doctors discovered a rare neuroepithelial tumor in his brain. By sequencing the genetic material of the mass, scientists found that the gene therapy payload had accidentally woven itself into the boy's own genome. Specifically, the viral delivery cassette fused with a human gene called PLAG1, which is known to drive tumor growth. Curiously, the tumor also contained a stray fragment of a different human chromosome, which researchers suspect was a manufacturing contaminant from when the viral vector was created. Thankfully, the story has a positive outcome so far. Surgeons successfully removed the tumor. Eight months after the operation, the patient shows no signs of the tumor returning and is actually demonstrating advanced cognitive development.

GEN1 min read
Gene Therapy

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Duchenne muscular dystrophy is a fatal neuromuscular disease caused by a broken or missing muscle protein. Recently, the company Regenxbio announced that its experimental gene therapy produced sufficiently high levels of a miniaturized version of this crucial protein in a clinical trial. By delivering a functional, smaller substitute to patients, the treatment aims to address the root cause of the condition. Following these promising early results, Regenxbio plans to use the clinical trial data to apply for accelerated approval from the Food and Drug Administration. However, we must view these developments with some caution. The initial reports do not disclose the actual size of the clinical trial, the detailed safety profile of the drug, or the exact quantitative protein levels the patients achieved.

STAT News1 min read
Gene Therapy

Scientists Unveil a Compact AI-Designed Alternative to Cas9

Gene editing tools like CRISPR are incredible, but the standard tool, Cas9, is quite bulky. This makes it hard to pack into the tiny delivery vehicles used in gene therapy. Now, researchers have used artificial intelligence and detailed 3D molecular mapping to engineer a much smaller alternative called M82. The team took a naturally occurring enzyme called Cas12l and used an AI language model to predict the best structural tweaks. In early lab experiments on human cells, the resulting M82 variant was highly effective. It achieved a 67.4 percent basic editing rate, matching the industry standard Cas9. Even more impressively, M82 outperformed Cas9 in a more complex type of editing called homology-directed repair, where a new piece of genetic code is smoothly inserted into the DNA. In preliminary tests, M82 successfully inserted genes 39 percent of the time. However, this technology is still in the early preclinical phase and requires testing in living organisms to confirm its real-world safety and effectiveness.

GEN1 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
First inside-the-body CRISPR gene therapy heads to the FDA — Daily Strand